FDA Grants Hemispherx Biopharma Extension in Its Pending New Drug Application (NDA) for the Treatment of Chronic Fatigue Syndrome (CFS)

PHILADELPHIA, Jan. 11, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the “Company” or “Hemispherx”) announced today that the Food and Drug Administration (“FDA”) granted an extension for the Company to modify its New Drug Application (“NDA”) in response to a Complete Response Letter (“CRL”) received November 25, 2009 for the Chronic Fatigue Syndrome (“CFS”) therapeutic indication. The extension will remain open while Hemispherx submits an amended NDA.